



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

June 19, 2007

Docket No. 03003073
Control No. 140294

License No. 37-06572-02

David T. Shannon
Chief Executive Officer
Temple Lower Bucks Hospital, Inc.
Bath Road and Orchard Avenue
Bristol, PA 19007

SUBJECT: TEMPLE LOWER BUCKS HOSPITAL, INC., LICENSE AMENDMENT,
CONTROL NO. 140294

Dear Mr. Shannon:

This refers to your license amendment request to add an authorized user and diagnostic uses of iodine-131. Enclosed with this letter is the amended license. Please note that the license has been updated in accordance with revisions to 10 CFR Part 35 and that a possession limit of 100 millicuries has been added for iodine-131.

In addition, it appears that a possible change of ownership (control) has occurred whereby Temple is no longer associated with this facility. Our letter dated June 4, 2007 provided the required information that must be submitted to support any change of ownership (control). This issue will be addressed further as part of the ongoing inspection, Inspection No. 2007-001. Please note that if a change of ownership (control) and/or a name/address change has occurred, you must also amend your license to reflect these changes.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Academic, and Industrial Uses of Nuclear Material**; then **Regulations, Guidance, and Communications**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 8:00 p.m. EST, Monday through Friday (except Federal holidays).

D. Shannon
Temple Lower Bucks Hospital, Inc.

2

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 49

cc:
Mark W. Ansley, M.D., Radiation Safety Officer

D. Shannon
Temple Lower Bucks Hospital, Inc.

3

DOCUMENT NAME: C:\FileNet\ML071700716.wpd

SUNSI Review Complete: PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	☒ N	DNMS/RI	☐	DNMS/RI	☐		
NAME	PLanzisera / <i>PAN</i> /							
DATE	6-19-07							

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Temple Lower Bucks Hospital, Inc. 2. Bath Road and Orchard Avenue Bristol, Pennsylvania 19007	In accordance with the letters dated March 16 and April 24, 2007, 3. License number 37-06572-02 is amended in its entirety to read as follows: 4. Expiration date January 31, 2011 5. Docket No. 030-03073 Reference No.	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Iodine 131 for diagnostic uses permitted by 10 CFR 35.300	7. Chemical and/or physical form A. Any B. Any C. Any	8. Maximum amount that licensee may possess at any one time under this license A. As needed B. As needed C. 100 millicuries
9. Authorized use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100. B. Any imaging and localization study permitted by 10 CFR 35.200. C. Any iodine-131 diagnostic study permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.		

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Bath Road at Orchard Avenue, Bristol, Pennsylvania
11. The Radiation Safety Officer for this license is Mark W. Ansley, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-06572-02Docket or Reference Number
030-03073

Amendment No. 49

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Philip Brackin, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

Lester Libfraind, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

Mark W. Ansley, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

Steven H. Kalchman, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

Richard D. Fleisher, D.O.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

Mario C. Giudici, M.D.

35.100; 35.200; Oral administration of sodium iodide iodine-131 for diagnostic studies

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
37-06572-02Docket or Reference Number
030-03073

Amendment No. 49

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated November 21, 2000 (ML003773905)



For the U.S. Nuclear Regulatory Commission

Original signed by Penny Lanzisera

Date June 19, 2007

By

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406